Skip to main content

Advertisement

SpringerLink
Log in

Durable Disease Control with Regorafenib in a Patient with Metastatic KIT-Mutated Colorectal Cancer

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Union for International Cancer Control's (UICC). New Global Cancer Data: GLOBOCAN 2018 (Acessed in 12 Jan 2020). Available from: https://www.uicc.org/news/new-global-cancer-data-globocan-2018

  2. Instituto Nacional de Câncer. Ministério da Saúde. Estatísticas de câncer (Accessed in 12 Jan 2020). Available from: https://www.inca.gov.br/numeros-de-cancer

  3. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–422.

    Article  Google Scholar 

  4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Colon Cancer. Version 2.2018. Fort Washington: National Comprehensive Cancer Network; 2018.

    Google Scholar 

  5. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–12.

    Article  CAS  Google Scholar 

  6. Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16:619–29.

    Article  CAS  Google Scholar 

  7. Van Cutsem E, Martinelli E, Cascinu S, et al. Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy: results of the large, single-arm, open-label phase IIIb CONSIGN study. Oncologist. 2019;24:185–92.

    Article  Google Scholar 

  8. Dhillo S. Regorafenib: a review in metastatic colorectal cancer. Drugs. 2018;78(5):1–12.

    Google Scholar 

  9. Salem ME, Petricoin E, Wellstein A, et al. Regorafenib in metastatic colorectal cancer: an exploratory biomarker trial. J Clin Oncol. 2016;34(4 suppl):TPS773–3.

  10. Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20(8):1070–82.

    Article  CAS  Google Scholar 

  11. Bachet JB, Hostein I, Le Cesne A, et al. Prognosis and predictive value of KIT exon 11 deletion in GISTs. Br J Cancer. 2009;101(1):7–11.

    Article  CAS  Google Scholar 

  12. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295–302.

    Article  CAS  Google Scholar 

  13. Zhang B, Wang J, Wang X, et al. Proteogenomic characterization of human colon and rectal cancer. Nature. 2014;513:382–7.

    Article  CAS  Google Scholar 

  14. Chen EC, Karl TA, Kalisky T, Gupta SK, O’Brien CA, Longacre TA, et al. KIT signaling promotes growth of colon xenograft tumors in mice and is up-regulated in a subset of human colon cancers. Gastroenterology. 2015;149:705–17.

    Article  CAS  Google Scholar 

  15. Korphaisarn K, Loree JM, Nguyen V, Coulson R, Holla V, Litzenburger BC, et al. Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature. Oncotarget. 2017;8(34):57882–8.

    Article  Google Scholar 

  16. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.

    Article  Google Scholar 

  17. Park HY, Kwon MJ, Kang HS, Kim YJ, Kim NY, Kim MJ, et al. Targeted next-generation sequencing of well-differentiated rectal, gastric, and appendiceal neuroendocrine tumors to identify potential targets. Hum Pathol. 2019;87:83–94.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology Department, Hospital Alemão Oswaldo Cruz, Rua Treze de Maio, 1815 – Bela Vista, São Paulo, SP, 01327-001, Brazil

    Jefferson Rios Pimenta

  2. Radiology Department, Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil

    Douglas Jorge Racy & Luciana Mejia Zapata

  3. Universidade Nove de Julho, São Paulo, Brazil

    Renata D’Alpino Peixoto

  4. Centro Paulista de Oncologia-Grupo Oncoclínicas, São Paulo, Brazil

    Renata D’Alpino Peixoto

Authors
  1. Jefferson Rios Pimenta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Douglas Jorge Racy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luciana Mejia Zapata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Renata D’Alpino Peixoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Renata D’Alpino Peixoto.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pimenta, J.R., Racy, D.J., Zapata, L.M. et al. Durable Disease Control with Regorafenib in a Patient with Metastatic KIT-Mutated Colorectal Cancer. J Gastrointest Canc 52, 784–787 (2021). https://doi.org/10.1007/s12029-020-00523-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-020-00523-8

Search

Navigation